TARS News & Events

Reports Q1 revenue $162.05M, consensus $148.73M. "XDEMVY is driving a fundamental shift in how Demodex blepharitis is diagnosed and treated," said Bobak Azamian, Chief Executive Officer and Chairman of Tarsus. "As we look across the business, every key signal is gaining momentum, and we are seeing the market expand as a result - reinforcing XDEMVY's expected growth trajectory toward potential peak sales exceeding $2 billion. Equally as exciting, XDEMVY validates a repeatable playbook for category creation. We are now scaling that approach across our pipeline, with several catalysts ahead that we believe will drive the next phase of growth and establish new standards of care."

Tarsus Pharmaceuticals announced that the first participant has been dosed in the Phase 2 clinical trial evaluating TP-05, a novel investigational oral therapy designed to potentially prevent Lyme disease by killing Lyme-infected ticks before disease transmission occurs.